Evidence map›Paper›PMID 39270649›Full record

ArticleAmerican journal of human genetics2024

Germline polygenic risk scores are associated with immune gene expression signature and immune cell infiltration in breast cancer.

Yuxi Liu, Cheng Peng, Ina S Brorson, Denise G O'Mahony, Rebecca L Kelly, Yujing J Heng, Gabrielle M Baker, Grethe I Grenaker Alnæs, Clara Bodelon, Daniel G Stover and 5 more

Abstract read
In one paragraph

Article in American journal of human genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The Breast Tumor Immune Microenvironment of DNA Double-Strand Break Repair Pathogenic Variant Carriers Is Enriched with Tumor-Associated Macrophages.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yuxi LiuDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Cheng PengChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Ina S BrorsonInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Denise G O'MahonyInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Rebecca L KellyCancer Prevention Fellowship Program, National Cancer Institute, Rockville, MD, USA; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Yujing J HengDepartment of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Gabrielle M BakerDepartment of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Grethe I Grenaker AlnæsDepartment of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo, Norway.
Clara BodelonDepartment of Population Science, American Cancer Society, Atlanta, GA, USA.
Daniel G StoverDivision of Medical Oncology, Stefanie Spielman Comprehensive Breast Center, Columbus, OH, USA; Department of Biomedical Informatics, Ohio State University, Columbus, OH, USA.
Eliezer M Van AllenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Cancer Program, The Broad Institute of MIT and Harvard, Cambridge, MA, USA.
A Heather EliassenDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Vessela N KristensenInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Department of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo, Norway.
Rulla M TamimiDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
Peter KraftDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. Electronic address: phillip.kraft@nih.gov.

Funding

Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, TAMIMI, RULLA M · 2000 to 2019
$77.8M
Risk Factors for Breast Cancer in Younger NursesR01CA050385 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 1989 to 2019
$32.3M
Life Course Cancer Epidemiology Cohort in WomenU01CA176726 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 2018 to 2025
$22.4M
Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3M
Premonopausal Hormone Levels and Risk of Breast CancerR01CA067262 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HANKINSON, SUSAN E · 2002 to 2011
$11.9M
BIOCHEMICAL MARKERS IN THE NURSES'HEALTH STUDY COHORTR01CA049449 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI HANKINSON, SUSAN E · 1989 to 2008
$11.3M
Epidemiologic StudiesU19CA148065 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI AHSAN, HABIBUL, BRUGGE, JOAN SIEFERT · 2010 to 2014
$10.6M
Assessing the role of androgens in breast cancer riskR01CA166666 · NCI · UNIVERSITY OF MASSACHUSETTS AMHERST · PI HANKINSON, SUSAN E · 2012 to 2015
$1.7M
Prediagnostic exposures, germline genetics, and triple negative breast cancer mutational and immune profilesU01CA260352 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI TAMIMI, RULLA M · 2023 to 2025
$1.3M
Prediagnostic exposures, germline genetics, and triple negative breast cancer mutational and immune profilesR01CA260352 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI KRAFT, PETER, TAMIMI, RULLA M · 2021 to 2022
$1.3M
Living beyond cancer: the short- and long-term cognitive effects of breast cancer and its treatment for cancer survivorsK01AG080030 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI Cheng Peng · 2023 to 2026
$524k
NCI NIH HHS P01 CA087969NCI NIH HHS R01 CA049449NCI NIH HHS R01 CA050385NCI NIH HHS R01 CA067262NCI NIH HHS R01 CA166666NCI NIH HHS R01 CA260352NCI NIH HHS U01 CA176726NCI NIH HHS U01 CA260352NCI NIH HHS U19 CA148065NCI NIH HHS UM1 CA186107NIA NIH HHS K01 AG080030
6 · The paper itself

Abstract

The tumor immune microenvironment (TIME) plays key roles in tumor progression and response to immunotherapy. Previous studies have identified individual germline variants associated with differences in TIME. Here, we hypothesize that common variants associated with breast cancer risk or cancer-related traits, represented by polygenic risk scores (PRSs), may jointly influence immune features in TIME. We derived 154 immune traits from bulk gene expression profiles of 764 breast tumors and 598 adjacent normal tissue samples from 825 individuals with breast cancer in the Nurses' Health Study (NHS) and NHSII. Immunohistochemical staining of four immune cell markers were available for a subset of 205 individuals. Germline PRSs were calculated for 16 different traits including breast cancer, autoimmune diseases, type 2 diabetes, ages at menarche and menopause, body mass index (BMI), BMI-adjusted waist-to-hip ratio, alcohol intake, and tobacco smoking. Overall, we identified 44 associations between germline PRSs and immune traits at false discovery rate q < 0.25, including 3 associations with q < 0.05. We observed consistent inverse associations of inflammatory bowel disease (IBD) and Crohn disease (CD) PRSs with interferon signaling and STAT1 scores in breast tumor and adjacent normal tissue; these associations were replicated in a Norwegian cohort. Inverse associations were also consistently observed for IBD PRS and B cell abundance in normal tissue. We also observed positive associations between CD PRS and endothelial cell abundance in tumor. Our findings suggest that the genetic mechanisms that influence immune-related diseases are also associated with TIME in breast cancer.

Indexed as

Breast NeoplasmsGenetic Predisposition to DiseaseMultifactorial InheritanceAdultFemaleGenetic Risk ScoreHumansMiddle AgedRisk FactorsTranscriptomeTumor Microenvironmentautoimmune diseasebreast cancerimmune gene expression signatureimmune infiltrationinflammatory bowel diseaseinterferon signalingpolygenic risk scoretumor immune microenvironment

Identifiers

PMID39270649
PMCPMC11480808

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.